on behalf of the ESMO Guidelines CommitteeAnn Oncol 2018; 29: iv192-iv237 (doi:10.1093/annonc/mdy275)The following corrections are made:In the section "Management of advanced/metastatic NSCLC, First-line treatment of EGFR-and ALK-negative NSCLC disease, regardless of PD-L1 status" 1. In KEYNOTE-189, patients with metastatic non-squamous NSCLC, PS 0-1, without sensitising EGFR or ALK mutations, were randomised to receive pemetrexed and a platinum-based ChT plus either 200 mg of pembrolizumab or placebo every 3 weeks for 4 cycles, followed by pembrolizumab or placebo for up to a total of 35 cycles plus pemetrexed maintenance therapy [96].

No abstract

No abstract

No abstract

physicians confirmed sOMD patients with brain MRI (91%, n¼403) and PET-CT (98%, n¼437). For mediastinum staging, most (64%, n¼285) respondents stated that histology/cytology should be obtained when PET-CT shows suspected lymph nodes or in case of a central primary tumor. Pathology proof of metastatic disease was necessary in sOMD for 315 (71%) physicians, and 37% (n¼163) acknowledged that histology should be obtained from at least from one metastatic site. Preferred primary outcome parameter in clinical trials of sOMD was overall survival (73%, n¼325). Conclusion: Although certain consensual answers were obtained (81% aimed to cure and >90% mandated baseline imaging with PET-CT and brain MRI), a number of issues remain unresolved and will require further discussion by a panel of experts to agree on a sOMD-d.